These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 12204574)

  • 1. Evaluation of controlled-release polar lipid microparticles.
    Savolainen M; Khoo C; Glad H; Dahlqvist C; Juppo AM
    Int J Pharm; 2002 Sep; 244(1-2):151-61. PubMed ID: 12204574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of polar lipid-hydrophilic polymer microparticles.
    Savolainen M; Herder J; Khoo C; Lövqvist K; Dahlqvist C; Glad H; Juppo AM
    Int J Pharm; 2003 Aug; 262(1-2):47-62. PubMed ID: 12927387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Xylitol as a potential co-crystal co-former for enhancing dissolution rate of felodipine: preparation and evaluation of sublingual tablets.
    Arafa MF; El-Gizawy SA; Osman MA; El Maghraby GM
    Pharm Dev Technol; 2018 Jun; 23(5):454-463. PubMed ID: 27681386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Efficacy, safety and tolerance of Felodipine controlled release tablets and Felodipine controlled release tablets associated combination therapy in the treatment of mild to moderate essential hypertension in China].
    Chen YY; Sun NL; Zhang WZ; Wu HY; Zhang L; Yu ZQ; Zhang FC; Xiang XP; Liu HL; Shen FR; Tao J; Zhao JA
    Beijing Da Xue Xue Bao Yi Xue Ban; 2007 Dec; 39(6):619-23. PubMed ID: 18087554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of poloxamer on the dissolution of felodipine and preparation of controlled release matrix tablets containing felodipine.
    Lee KR; Kim EJ; Seo SW; Choi HK
    Arch Pharm Res; 2008 Aug; 31(8):1023-8. PubMed ID: 18787792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of supercritical fluid extraction for sample preparation of sustained-release felodipine tablets.
    Howard AL; Shah MC; Ip DP; Brooks MA; Strode JT; Taylor LT
    J Pharm Sci; 1994 Nov; 83(11):1537-42. PubMed ID: 7891270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced Oral Bioavailability of Felodipine from Solid Lipid Nanoparticles Prepared Through Effervescent Dispersion Technique.
    He Y; Zhan C; Pi C; Zuo Y; Yang S; Hu M; Bai Y; Zhao L; Wei Y
    AAPS PharmSciTech; 2020 Jun; 21(5):170. PubMed ID: 32529303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of solubilizers in the drug release testing of hydrophilic matrix extended-release tablets of felodipine.
    Abrahamsson B; Johansson D; Torstensson A; Wingstrand K
    Pharm Res; 1994 Aug; 11(8):1093-7. PubMed ID: 7971707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A study on maize proteins as a potential new tablet excipient.
    Georget DM; Barker SA; Belton PS
    Eur J Pharm Biopharm; 2008 Jun; 69(2):718-26. PubMed ID: 18294824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma concentration profiles and antihypertensive effect of conventional and extended-release felodipine tablets.
    Blychert E; Wingstrand K; Edgar B; Lidman K
    Br J Clin Pharmacol; 1990 Jan; 29(1):39-45. PubMed ID: 2404502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of biorelevant saliva-based dissolution for optimisation of orally disintegrating formulations of felodipine.
    Ali J; Zgair A; Hameed GS; Garnett MC; Roberts CJ; Burley JC; Gershkovich P
    Int J Pharm; 2019 Jan; 555():228-236. PubMed ID: 30465852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application of PVP/HPMC miscible blends with enhanced mucoadhesive properties for adjusting drug release in predictable pulsatile chronotherapeutics.
    Karavas E; Georgarakis E; Bikiaris D
    Eur J Pharm Biopharm; 2006 Aug; 64(1):115-26. PubMed ID: 16675210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using Flory-Huggins phase diagrams as a pre-formulation tool for the production of amorphous solid dispersions: a comparison between hot-melt extrusion and spray drying.
    Tian Y; Caron V; Jones DS; Healy AM; Andrews GP
    J Pharm Pharmacol; 2014 Feb; 66(2):256-74. PubMed ID: 24192445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Felodipine β-cyclodextrin complex as an active core for time delayed chronotherapeutic treatment of hypertension.
    Pagar KP; Vavia PR
    Acta Pharm; 2012 Nov; 62(3):395-410. PubMed ID: 23470351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Solid-state characterization of Felodipine-Soluplus amorphous solid dispersions.
    Lu J; Cuellar K; Hammer NI; Jo S; Gryczke A; Kolter K; Langley N; Repka MA
    Drug Dev Ind Pharm; 2016; 42(3):485-96. PubMed ID: 26530290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapidly absorbed orodispersible tablet containing molecularly dispersed felodipine for management of hypertensive crisis: development, optimization and in vitro/in vivo studies.
    Basalious EB; El-Sebaie W; El-Gazayerly O
    Pharm Dev Technol; 2013; 18(2):407-16. PubMed ID: 22339303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Analysis and evaluation of the impurity of felodipine and its tablets].
    Zhang N; Yu LJ; Li J; Tong JW; Meng J; Zhang QM; Shi YQ
    Yao Xue Xue Bao; 2012 Feb; 47(2):223-8. PubMed ID: 22512035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced dissolution of naproxen from pure-drug, crystalline nanoparticles: A case study formulated into spray-dried granules and compressed tablets.
    Braig V; Konnerth C; Peukert W; Lee G
    Int J Pharm; 2019 Jan; 554():54-60. PubMed ID: 30278257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Formulation, evaluation and optimization of the felodipine nanosuspension to be used for direct compression to tablet for in vitro dissolution enhancement.
    Mori D; Makwana J; Parmar R; Patel K; Chavda J
    Pak J Pharm Sci; 2016 Nov; 29(6):1927-1936. PubMed ID: 28375107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmaceutical acrylic beads obtained by suspension polymerization containing cellulose nanowhiskers as excipient for drug delivery.
    Villanova JC; Ayres E; Carvalho SM; Patrício PS; Pereira FV; Oréfice RL
    Eur J Pharm Sci; 2011 Mar; 42(4):406-15. PubMed ID: 21241802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.